ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Minority Professional Training Concept Gets Approval Of NCAB

March 1, 1991

St. Jude Begins $100 Million Expansion Program

December 4, 1987

In Brief: U – South Western Wins BMS Grant; ONS Gets $1.6 M; Unilever Chair In Diet Formed At CINJ

May 7, 1999

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

July 28, 1989

Oncology Unit – How To Plan, Start It

February 10, 1978

In Brief: DeVita Changes His Mind, Agrees To Head Treatment DIV; Contracts Chief Carl Fretts Moves Up To NIH

October 4, 1974